Advanced therapy in familial hypercholesterolemia

Area of Science:

• Cardiology
• Genetics
• Pediatrics

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder leading to significantly elevated LDL-C levels.
• Children with FH face an increased risk of early-onset atherosclerosis and cardiovascular disease.

Purpose of the Study:

• To review current recommendations for diagnosing and treating pediatric FH.
• To assess the safety and efficacy of advanced therapies for children with FH.
• To explore strategies for managing elevated LDL-C in pediatric patients.

Main Methods:

• Literature review of current guidelines and clinical studies on FH management in children.
• Analysis of data on the efficacy and safety of statins, monoclonal antibodies, PCSK9 inhibitors, and ANGPTL3 inhibitors in pediatric populations.
• Focus on treatment outcomes for patients with homozygous and heterozygous FH.

Main Results:

• High-intensity statin therapy may be insufficient for some pediatric FH patients.
• Monoclonal antibodies, PCSK9 inhibitors (e.g., evolocumab), and ANGPTL3 inhibitors (e.g., evinacumab) show promise as adjunct treatments.
• Evinacumab demonstrated higher efficacy than evolocumab in limited pediatric studies for homozygous FH.

Conclusions:

• Early diagnosis and specialist consultation are crucial for children with FH.
• Advanced therapies like PCSK9 and ANGPTL3 inhibitors can significantly reduce LDL-C when statins are inadequate.
• Further long-term research on novel therapies in pediatric FH is essential to confirm safety and efficacy.